Naftifine
Naftifine, Naftin (naftifine) is a small molecule pharmaceutical. Naftifine was first approved as Naftin on 1988-02-29. It is used to treat mycoses and tinea pedis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Naftifine, Naftin (discontinued: Naftin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Naftifine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NAFTIN | Sebela Pharmaceuticals | N-019356 RX | 1990-06-18 | 1 products, RLD, RS |
| NAFTIN | Sebela Pharmaceuticals | N-019599 RX | 2012-01-13 | 1 products, RLD, RS |
| NAFTIN | Sebela Pharmaceuticals | N-204286 RX | 2013-06-27 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| naftifine hydrochloride | ANDA | 2025-07-07 |
| naftin | New Drug Application | 2025-07-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycoses | — | D009181 | B35-B49 |
| tinea pedis | EFO_0007512 | D014008 | B35.3 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tinea | D014005 | EFO_0007510 | B35.4 | 4 | 1 | 6 | 3 | — | 14 |
| Tinea pedis | D014008 | EFO_0007512 | B35.3 | 4 | — | 4 | 1 | — | 9 |
| Tinea cruris | D000084002 | — | B35.6 | 1 | — | 2 | 1 | — | 4 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tinea capitis | D014006 | — | B35.0 | — | 1 | — | — | — | 1 |
| Onychomycosis | D014009 | — | B35.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Naftifine |
| INN | naftifine |
| Description | Naftifine is a tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections. It has a role as an EC 1.14.13.132 (squalene monooxygenase) inhibitor and a sterol biosynthesis inhibitor. It is a member of naphthalenes, a tertiary amine and an allylamine antifungal drug. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 65472-88-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL626 |
| ChEBI ID | 7451 |
| PubChem CID | 47641 |
| DrugBank | DB00735 |
| UNII ID | 4FB1TON47A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Naftifine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 531 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
124 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use